PL reduced its FY24E and FY25E EPS by 10% and 6% as they factor in lower margins ex of gRevlimid. The brokerage downgraded Dr Reddy's stock to 'Reduce' from 'Buy' with a revised target price of Rs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback